Biologics' cost burden and biosimilar goals

J. Carlisle Larsen outlines biologics' disproportionate spending share and the FDA's aim to expand biosimilar competition.

Play episode from 04:05

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!